TAG:
diagnostic testing
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
New Competitors Line Up In Oncology Marketplace
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
No Disruptive Technology In Lab Industry’s Future
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular tech…
Looking at Fast-Growth And Slow-Growth Areas In Diagnostic Testing
CEO SUMMARY: This exclusive intelligence briefing predicts how specific new technologies may drive changes in the laboratory-testing marketplace during the next five years. The key message is that change is expected to be incremental, not disruptive—given the technology known to be in d…
Are Two Blood Brothers Using Economic Clout?
CEO SUMMARY: Quest Diagnostics Incorporated and Laboratory Corporation of America now dominate the national marketplace for testing referred by physicians’ offices. Release of their second quarter earnings reports provides the first look at their performance following the acquisitions i…
“State of Industry” Report On Molecular Diagnostics
CEO SUMMARY: Enterprise Analysis Corporation has launched an ambitious survey that will include 150 laboratories performing molecular testing in the United States. Last week it released information about the first 51 labs contacted in this effort. The survey provides an intriguing look at…
Boost for Labs: Study Reveals Big Care Gap
CEO SUMMARY: This research project involved 13,000 patients and a detailed review of medical records. The startling conclusion: the health system provides proper diagnosis and treatment only 55% of the time! Because of the study’s depth, it provides a compelling argument that the nation…
LabCorp’s MacMahon Provides Insights About Lab Marketplace
CEO SUMMARY: Pathologists will be particularly interested in what Thomas MacMahon has to say about the evolution of laboratory medicine. As Chairman, President, and CEO of Laboratory Corporation of America Holdings, he has continuous access to some of the best strategic analysis about the…
Quest Finally Owns Unilab, New Market Cycle To Begin
PERSISTENCE FINALLY PAID OFF for Quest Diagnostics Incorporated. On February 26, it took ownership of Unilab Corporation, capping almost 11 months of effort. In completing this acquisition, Quest Diagnostics completes the two blood brothers’ acquisition sweep of m…
Laboratories Sit Squarely Between New Genetics and Today’s Medicine
“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.